h 12 41303 1171602000 false 1172552400 1165 330 110 400253

2/16/2007--Introduced.<br/>Swift Approval, Full Evaluation Drug Act or the SAFE Drug Act - Amends the Federal Food, Drug, and Cosmetic Act to authorize the Secretary of Health and Human Services to: (1) order postmarket studies of approved drugs upon receiving evidence of a significant issue regarding the safety or lack of effectiveness of such a drug; and (2) establish restrictions on the distribution or use of the drug during the period in which the study is conducted.<br/>Directs the Secretary to amend regulations to require postmarket studies of drugs approved under an accelerated approval process for new drugs for serious or life-threatening illnesses. Deems a drug or device to be misbranded if there is a failure to comply with requirements under this Act.<br/>Prohibits discrimination against individuals who provide information in an investigation or proceeding regarding a violation of any law, rule, or regulation, censorship, distortion, or suppression of scientific information, research, or analysis, or the willful disclosure of false, misleading, or incomplete scientific information.<br/>Authorizes Food and Drug Administration (FDA) officers, employees, and sponsored individuals to publish in peer-reviewed journals and other scientific publications and make oral presentations at professional society meetings and other meetings of their peers, with certain exceptions.<br/>Prohibits an FDA officer or employee from directing any other FDA officer or employee to: (1) censor, distort, or suppress any scientific research, analysis, opinion, or recommendation; or (2) willfully disclose scientific information that is false, misleading, or incomplete.<br/>Requires the Secretary to publish a summary statement of the scientific basis for approval of any new drug and how the final decision balanced the risk and benefits within 48 hours after approval of an application.<br/>

1172552400 2007-02-27 Thu Nov 06 19:23:08 -0600 2008 introduced 41303 'act':3 'drug':2 'safe':1 44411 short introduced 41303 'act':6 'drug':5 'full':3 'evalu':4 'swift':1 'approv':2 44412 short introduced 41303 'act':9 'use':20 'drug':6,22 'food':5 'safe':17 'addit':12 'amend':2 'ensur':15 'feder':4 'author':13 'cosmet':8 'effect':19 'purpos':33 'certain':28 'protect':26 'individu':29 'establish':11,24 'whistleblow':25 41500 official action 41303 1172552400 Tue Feb 27 00:00:00 -0600 2007 124632 Referred to the Subcommittee on Health. M000133 1946-07-11 5999 2108 Rayburn House Office Building http://markey.house.gov/index.php?option=com_email_form&Itemid=124 7 202-226-0092 Edward 'd':4 '-7':6 'ed':9 'ma':5 'rep':1 'edward':2,7,10 'markey':3,8,11 M 400253 Markey Edward_J._Markey J. Rep. Edward Markey [D, MA-7] 3103 Ed N00000270 8280 Democrat 202-225-2836 Roman Catholic MA Ed Edward Markey 3.35 http://markey.house.gov/ RepMarkey E000215 1942-12-13 2827 205 Cannon House Office Building https://forms.house.gov/eshoo/webforms/issue_subscribe.htm 14 202-225-8890 Anna 'd':4 'ca':5 '-14':6 'rep':1 'anna':2,7,9 'eshoo':3,8,10 F 400124 Eshoo Anna_G._Eshoo G. Rep. Anna Eshoo [D, CA-14] 1314 N00007335 7903 Democrat 202-225-8104 Catholic CA Anna Eshoo 2.8 http://eshoo.house.gov/ RepAnnaEshoo action 41303 1172552400 Tue Feb 27 00:00:00 -0600 2007 124632 Referred to the Subcommittee on Health. action 41303 1171688400 Sat Feb 17 00:00:00 -0600 2007 105689 Introductory remarks on measure. (CR E390-391) action 41303 1171688400 Sat Feb 17 00:00:00 -0600 2007 115317 Sponsor introductory remarks on measure. (CR E390-391) introduced 41303 1171602000 Fri Feb 16 00:00:00 -0600 2007 93953 action 41303 1171602000 Fri Feb 16 00:00:00 -0600 2007 93954 Referred to the House Committee on Energy and Commerce.